Combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients undergoing surgery for non-small cell lung cancer

Abstract

The aim of this study was to investigate the usefulness of a novel inflammation-based prognostic system, called COP-LMR (combination of platelet count and lymphocyte to monocyte ratio), for predicting postoperative survival of patients with non-small cell lung cancer (NSCLC). COP-LMR was calculated on the basis of the obtained data. Patients with both an elevated platelet count (PLT) (>30 × 104mm-3) and a low LMR (<3.6) were assigned a score of 2, and patients with one or none of the parameters were assigned a score of 1 or 0, respectively. A total of 1120 patients who underwent complete resection were enrolled in this study. Multivariate analysis revealed that COP-LMR is an independent prognostic factor for disease-free survival (DFS) (P<0.001) and overall survival (OS) (P<0.001). Kaplan-Meier analysis and the log-rank test revealed that COP-LMR stratified the patients into 3 independent groups (P<0.001). In conclusion, COP-LMR is a potential prognostic biomarker in patients undergoing surgery for NSCLC.

Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion

“…Our results showed that COP-LMR was an independent predictor for shorter overall survival and progression free survival in stage IV NSCLC. Liu et al have shown that COP-LMR has prognostic value in patients with NSCLC who underwent curative resection [ 21 ]. On the other hand, our study population were comprised of stage IV NSCLC patients with MPE.…”

“…Hence, platelet counts are associated with cancer progression. The cutoff value of platelet counts has not been clearly defined yet, although platelet count of 30.0 x 10 4 mm -3 is often used in previous publications on prognostic value of platelet in cancer [ 21 , 35 ]. Consistent with these previous publications, the cutoff value of platelet count in our study was also 30.0 x 10 4 mm -3 .…”

“…In addition to single inflammatory biomarkers, combinations of single biomarkers with known predictability have also been evaluated for their prognostic values [ 12 , 20 ]. A combination of platelet and LMR (abbreviated as COP-LMR) has been recently evaluated as systemic inflammatory marker for prognostication in lung cancer [ 21 ]. While previous study on COP-LMR has evaluated its prognostic value in NSCLC patients who underwent curative resections [ 21 ], the combination of these two markers has not been evaluated in advanced NSCLC yet.…”

“…A combination of platelet and LMR (abbreviated as COP-LMR) has been recently evaluated as systemic inflammatory marker for prognostication in lung cancer [ 21 ]. While previous study on COP-LMR has evaluated its prognostic value in NSCLC patients who underwent curative resections [ 21 ], the combination of these two markers has not been evaluated in advanced NSCLC yet. In this study, we evaluated the prognostic value of COP-LMR in stage IV NSCLC with malignant pleural effusion under active anticancer treatment by assessing its predictability for overall survival and disease progression.…”

Human Cancer and Platelet Interaction, a Potential Therapeutic Target

“…In addition, long-term application of low-dose anti-platelet drugs, such as aspirin, inhibits cancer metastasis and significantly reduces cancer incidence [ 31 , 32 ]. Together these results suggest that platelet activation is a potential target and prognosis marker for cancer treatment [ 29 , 33 , 34 ].…”